Targeting claudin‐4 enhances chemosensitivity in breast cancer

Triple negative breast cancer (TNBC) is characterized by highly aggressive phenotype, limited treatment options and a poor prognosis. In the present study, we examined the therapeutic effect of anti–claudin (CLDN)‐4 extracellular domain antibody, 4D3, on TNBC. When the expression of CLDN4 and CLDN1...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Yi, Kishi, Shingo, Sasaki, Takamitsu, Ohmori, Hitoshi, Fujiwara‐Tani, Rina, Mori, Shiori, Goto, Kei, Nishiguchi, Yukiko, Mori, Takuya, Kawahara, Isao, Kondoh, Masuo, Kuniyasu, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226188/
https://www.ncbi.nlm.nih.gov/pubmed/32086991
http://dx.doi.org/10.1111/cas.14361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226188/
https://www.ncbi.nlm.nih.gov/pubmed/32086991
http://dx.doi.org/10.1111/cas.14361

Ejemplares similares